Sally E. Hay-Baron

St Leonards, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.

Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.

Journal: Journal for immunotherapy of cancer

Published: January 20, 2026

Real-world outcomes in patients with hormone receptor positive, human epidermal growth factor receptor 2 receptor-negative advanced breast cancer and visceral metastases at baseline - advanced hormone receptor positive breast cancer registry in Australia.

Real-world outcomes in patients with hormone receptor positive, human epidermal growth factor receptor 2 receptor-negative advanced breast cancer and visceral metastases at baseline - advanced hormone receptor positive breast cancer registry in Australia.

Journal: Internal medicine journal

Published: January 14, 2026

Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: December 17, 2025

The gut microbiome as a potential predictive biomarker for breast cancer: emerging association and geographic differences.

The gut microbiome as a potential predictive biomarker for breast cancer: emerging association and geographic differences.

Journal: Frontiers in oncology

Published: July 15, 2025

Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

Journal: British journal of cancer

Published: April 16, 2025

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial.

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial.

Journal: Nature communications

Published: December 23, 2024

Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.

Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.

Journal: Nature medicine

Published: December 09, 2024

Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy.

Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy.

Journal: JAMA network open

Published: August 09, 2024

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.

Journal: Nature medicine

Published: July 29, 2024

Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.

Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.

Journal: The Lancet. Oncology

Published: July 17, 2024

Medicine Access Programmes: what do patients think - a patient-reported outcome study on ribociclib in metastatic breast cancer in Australia.

Medicine Access Programmes: what do patients think - a patient-reported outcome study on ribociclib in metastatic breast cancer in Australia.

Journal: Internal medicine journal

Published: February 16, 2024

Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.

Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 14, 2023

Showing 1-12 of 37

Last Updated: 09/26/2026